Top Story

PD-L1 expression, CD8+ T-cell counts associated with shorter OS in mRCC

January 28, 2015

Higher levels of PD-L1 expression, as well as PD-L1 expression plus tumor CD8+ T-cell counts, were linked to shorter survival in patients with metastatic renal cell carcinoma who received VEGF-targeted therapy, according to results from a randomized controlled trial.

Poor outcomes in metastatic renal cell carcinoma (mRCC) have been associated with PD-L1 expression; however, this correlation has not been evaluated in patients with advanced RCC who receive VEGF-targeted agents.

Association News

Bladder Cancer Advocacy Network announces award recipients

January 22, 2015
The Bladder Cancer Advocacy Network (BCAN) named William Kim, MD, the recipient of its 2014 Bladder Cancer Research Innovation Award.Kim, associate professor of…
Robert J. Motzer, MD In the Journals

Nivolumab showed antitumor activity in patients with metastatic renal cell carcinoma

January 13, 2015
Nivolumab showed antitumor activity with a manageable safety profile in previously treated patients with clear-cell metastatic renal cell carcinoma, according to results…
Cora Sternberg In the Journals

Immediate chemotherapy after radical cystectomy failed to extend OS

January 8, 2015
Patients with urothelial carcinoma of the bladder who underwent immediate chemotherapy after radical cystectomy or bilateral lymphadenectomy demonstrated comparable OS…
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Toni K. Choueiri, MD In the Journals

PD-L1 expression, CD8+ T-cell counts associated with shorter OS in mRCC

January 28, 2015
Higher levels of PD-L1 expression, as well as PD-L1 expression plus tumor CD8+ T-cell counts, were linked to shorter survival in patients with…
Association News

Bladder Cancer Advocacy Network announces award recipients

January 22, 2015
The Bladder Cancer Advocacy Network (BCAN) named William Kim, MD, the recipient of its 2014 Bladder Cancer Research Innovation Award.Kim, associate…
Robert J. Motzer, MD In the Journals

Nivolumab showed antitumor activity in patients with metastatic renal cell carcinoma

January 13, 2015
Nivolumab showed antitumor activity with a manageable safety profile in previously treated patients with clear-cell metastatic renal cell carcinoma…
Cora Sternberg In the Journals

Immediate chemotherapy after radical cystectomy failed to extend OS

January 8, 2015
Patients with urothelial carcinoma of the bladder who underwent immediate chemotherapy after radical cystectomy or bilateral lymphadenectomy…
Michael Hauptmann, PhD In the Journals

Radiotherapy for testicular cancer increased risk for subsequent stomach cancer

January 6, 2015
Survivors of testicular cancer who underwent abdominal radiotherapy demonstrated long-term elevated risk for subsequent stomach cancers, according to…
In the Journals

Bisphosphonate prescriptions low among men who underwent ADT

January 2, 2015
Although guidelines recommend bisphosphonates for men who initiate androgen deprivation therapy, prescriptions for these agents in this patient…
In the Journals

Laparoscopic radical cystectomy conferred favorable long-term survival outcomes

December 29, 2014
Patients with muscle-invasive or high-risk bladder cancer experienced favorable RFS, OS and cancer-specific survival outcomes after undergoing…
In the Journals

Adjuvant chemotherapy regimen safe, feasible for stage I nonseminomatous germ cell tumors

December 23, 2014
Adjuvant treatment with one cycle of modified bleomycin, etoposide and cisplatin chemotherapy appeared safe and effective for patients with clinical…
In the Journals

Observation most common adjuvant management for stage I testicular seminoma

December 16, 2014
The use of observation after orchiectomy has significantly increased and is now the most common form of adjuvant management for patients with stage I…
Helen Colhoun In the Journals

Pioglitazone, rosiglitazone did not increase bladder cancer risk in patients with type 2 diabetes

December 4, 2014
The cumulative use of pioglitazone or rosiglitazone to treat type 2 diabetes was not associated with bladder cancer in a pooled analysis of six…
More Headlines »
morganatic-roan
morganatic-roan